D. Hofmann

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

N. Harbeck, O. Gluz, R. Kates, 2013, Trials.

Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

S. Shak, N. Harbeck, O. Gluz, 2015 .

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

S. Shak, N. Harbeck, O. Gluz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.

M. Rezai, S. Shak, N. Harbeck, 2014 .

Genomic Profiling in Luminal Breast Cancer

N. Harbeck, O. Gluz, C. Liedtke, 2013, Breast Care.

Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine

M. Rezai, S. Shak, N. Harbeck, 2013 .

Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition.

H. Tesch, J. Hornberger, N. Harbeck, 2015 .

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2015 .